Back to Studies

Study analysis · Brain Communications · 2022

Vitamin B supplements lower homocysteine but don't stop brain damage in people with HIV – here's why the link isn't what we thought.

Taking vitamin B pills lowered a blood marker of vitamin deficiency by 35%, but it didn't reduce a marker of nerve damage or improve thinking skills in people with well-treated HIV.

Reading level
Moderate certainty
Level 1b · Individual RCTAssociation, not causationNo causal claims

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study tested if taking vitamin B pills could reduce damage to brain cells in people with HIV. The researchers gave some people vitamin B and others no treatment, then checked a marker of brain damage. The vitamins lowered a substance called homocysteine in the blood, but they did not lower the brain damage marker. So the study shows that taking these vitamins does not seem to protect the brain from injury.

What’s the bottom line?

This study tested whether vitamin B supplements could reduce brain cell damage in people with HIV whose virus is well-controlled by medicine. The researchers measured a substance in the blood called homocysteine (linked to vitamin deficiency) and a marker of brain injury called neurofilament light (NfL). They gave half the participants vitamin B pills for a year.

How strong is this study?

This study was a randomized controlled trial, which is a strong type of study because it randomly decides who gets the treatment and who doesn't. However, it was 'open-label,' meaning both the doctors and patients knew who was getting the vitamins, which can sometimes affect results. Also, the study was small and only included people from one hospital in Sweden. So while it's a good study, we need to be careful about applying the results to everyone.

Reporting

40 / 100

  • COI disclosure+40/40
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

63 / 100

  • Randomization+20/20
  • Blindingnot blinded
  • Control group+15/15
  • Sample size (n=61)+5.3/20
  • Follow-up+10/10
Publication

100 / 100

Statistical

100 / 100

  • P-values+15/15
  • Effect size+20/20
  • Confidence intervals+15/15
  • Pre-registration+15/15

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
75

75 / 100

Probability of being correct

Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.

This design cannot establish causation — the findings describe an association, not a cause. This RCT can establish causation for the effect of vitamin B supplementation on homocysteine levels (significant decrease), but for the primary outcomes (plasma NfL and cognitive function), the study found no significant effect, so it does not support a causal claim. Limitations include open-label design (no blinding), small sample size (n=61), single-center, and modified cross-over design.

Minor COI

Minor conflicts that may slightly influence the study

Not Disclosed

The study used a commercial vitamin B supplement (TrioBe, Meda), but no conflict of interest declaration or funding statement is provided. The results were negative, reducing bias risk.

Undisclosed — Suspicious

Conflict Details

not specified
Non-Financial

Meda: Provided study drug (TrioBe tablets) but no financial support explicitly stated

Independent Analysis Safeguards

  • Randomized controlled trial design
  • Allocation concealment
  • Standard statistical methods used
  • Study conducted at academic institution

No COI declaration was found in the text. The study appears academically conducted, but lack of disclosure is a concern.

Key takeaways

  1. 01

    Vitamin B pills lowered homocysteine by 35%, but there was no difference in the brain injury marker NfL between the vitamin group and the control group.

  2. 02

    Cognitive tests also showed no improvement.

  3. 03

    These results suggest that even though vitamin B can fix a vitamin imbalance, it does not seem to stop ongoing brain injury in this population.

Surprising findings

  • Vitamin B supplementation reduced homocysteine by 35% but did not lower NfL or improve cognition.Common belief holds that high homocysteine is toxic to nerves, so lowering it should help. This study shows that in this population, the link is not causal via B vitamin deficiency.
  • 49% of participants had low-normal vitamin B12 levels (<300 pmol/L) and 41.4% had low-normal folate (<10 nmol/L), yet only one was truly B12 deficient.Even suboptimal vitamin levels were common, but correcting them didn't affect nerve injury. This suggests the body's vitamin status isn't the main driver of neuronal damage in well-treated HIV.

Practical takeaways

If you have HIV and your homocysteine is high, a B vitamin supplement will lower it – but don't expect it to improve your brain fog or memory based on current evidence.

This study was open-label, small (n=61), and lacked CSF measurements. It only applies to virally suppressed individuals with elevated homocysteine.

medium confidence

Monitor NfL levels? Not yet – but ask your doctor. Researchers are exploring it as a routine marker. For now, focus on proven brain-health strategies: exercise, diet, sleep, and viral suppression.

NfL testing is not widely available and normal ranges vary by age. It's still investigational for HIV clinical care.

medium confidence

For content creators: Use this study to challenge the 'vitamin cure' narrative. Emphasize that science is messy – a correlation (homocysteine & NfL) doesn't mean causation.

Always cite the limitations (open-label, small sample) and don't overgeneralize to HIV-negative populations.

high confidence

Why this study matters

The Homocysteine-NfL Puzzle

At screening, higher homocysteine levels were linked to higher levels of the nerve damage marker NfL (r = 0.35, p < 0.0001). But when vitamin B supplements slashed homocysteine by 35% (from 15.7 to 10.3 μmol/L), NfL barely budged (−6.5% change, p = 0.39).

It challenges the simple idea that lowering homocysteine automatically protects the brain. The correlation may be due to other factors like inflammation or oxidative stress.

No Brain Boost from B Vitamins

Cognitive function, measured by the Cogstate battery, showed no improvement with vitamin B supplementation (z-score difference −0.08, p = 0.53). Even after 24 months of treatment, there was no effect.

Many people take B vitamins hoping to sharpen their thinking. This study shows that in people with HIV, correcting a vitamin imbalance doesn't translate to better brain performance.

Hidden Nerve Damage Despite Suppressed HIV

39.3% of participants had NfL levels above age-adjusted norms, meaning ongoing nerve cell injury even though their HIV was well-controlled (viral load <50 copies/mL).

It highlights that 'undetectable' HIV doesn't mean 'no damage'. The virus may still cause harm through other pathways, like immune activation or metabolic issues.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.